<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="172162">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00855010</url>
  </required_header>
  <id_info>
    <org_study_id>112008-047</org_study_id>
    <secondary_id>1K23RRO24470-01</secondary_id>
    <nct_id>NCT00855010</nct_id>
    <nct_alias>NCT00896116</nct_alias>
  </id_info>
  <brief_title>Pioglitazone on Pancreatic Steatosis and Bone Health</brief_title>
  <official_title>Effect of Pioglitazone on Pancreatic Steatosis and Bone Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized, double blind, placebo controlled trial evaluating the effect of pioglitazone on
      pancreatic fat content and bone turnover markers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pancreatic fat content</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone turnover markers</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beta-cell function</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hepatic fat content</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subcutaneous fat area</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visceral fat area</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone mineral density</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body fat</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Obesity</condition>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>pioglitazone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pioglitazone tablet 45 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo pill once daily (look-alike pill which contains no active ingredients)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone</intervention_name>
    <description>pioglitazone 45 mg daily</description>
    <arm_group_label>pioglitazone</arm_group_label>
    <other_name>Actos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>one daily</description>
    <arm_group_label>placebo pill</arm_group_label>
    <other_name>Placebo tablet resembling pioglitazone 45 mg.</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Fat level in the pancreas above 4% (measurement done by us with an MRI)

          -  English speaker

          -  over 21 years old

        Exclusion Criteria:

          -  contraindication to MRI

          -  anemia

          -  pregnancy or desire to conceive

          -  use of unapproved medications

          -  prior pancreatic disease

          -  use of more then 2 alcoholic drinks every day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <lastchanged_date>June 23, 2016</lastchanged_date>
  <firstreceived_date>February 27, 2009</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Ildiko Lingvay</investigator_full_name>
    <investigator_title>MD, MPH, MSCS</investigator_title>
  </responsible_party>
  <keyword>Pioglitazone</keyword>
  <keyword>prediabetes</keyword>
  <keyword>diabetes</keyword>
  <keyword>obesity</keyword>
  <keyword>Pancreatic fat</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
